The main objective of the Project is to create BEAMER, a disease-agnostic behavioral and adherence model for improving quality, health outcomes and cost-effectiveness of healthcare, through improving the quality of life of individuals, enhance healthcare accessibility and sustainability. The model will allow for tailoring to individual?s needs, using Real World Data captured from patients? behaviors and health system information, transforming the way healthcare stakeholders engage with patients to optimize understanding of their condition and adherence levels throughout their patient journey. BEAMER is driven by a set of Ontology, Epistemology and Methodology principles, supported by Artificial Intelligence, Natural Language Processing, and Machine Learning. BEAMER will optimize the disease-agnostic adherence model by real-life testing proof-of-concept in 18 different pilots in Norway, Spain, the Netherlands, Germany, Portugal, and Italy, including over 18,000 patients (3000 patients in each thematic area). BEAMER will be embodied in an open source European searchable database, continuously updated, validated and optimized by empirical evidence and new insights, available to all stakeholders and adaptable for future developments in healthcare. Finally, extensive efforts will be directed to develop and implement dissemination and communication activities that increase exploitation and sustainability of BEAMER.

PUREMIND will deliver the first Integrated Mental Healthcare Ecosystem (IMHE) to predict/early identify Mental Health Disorders (MHD) and create more optimal personalised interventions to prevent MHD and thereby improving wellbeing in children, adolescents, and young adults (0–25 years). The ecosystem will mitigate key challenges associated with MHDs, specifically 1)Detection: 1 in 7 undetected and untreated MHD cases, 2)Efficiency of treatment: lack of tools and guidelines for personalised multidisciplinary interventions that work, 3)Access to Support and Care: long waiting times for care due to lack of trained personnel, 4)Inequality: disparate and inadequate inter- and intra-country mental healthcare services and 5)Modern Cultures and Lifestyle: the increasingly recognised risk factor of digital addiction resulting in sedentary, socially isolated lifestyle contributing to MHD. These will be addressed by PUREMIND’s approach of combining analytical modelling of dynamical systems in the cyber-physical context of a subject’s personal natural environment-gene-gut-brain-MHD interactions process creating a much-needed personalised intervention synthesis framework that will be exploited by an AI engine to deliver optimised personalised intervention, and a unique digital twin educating young people how MHD might develop depending on their environment and lifestyle. These 2 components will be combined in an accessible/ adaptable mobile app MyMind to measure at scale and allow a subject to seamlessly access a 4-tier service architecture involving family, community, clinical and emergency services, to support prediction/early detection of MHD, empowering them to monitor their own mental health at home/educational/community settings and taking preventive actions against MHD. The IMHE will be designed using Implementation Science approach and will be validated in a 12month pilot study in 7 European countries and 2 LMICs covering different socioeconomic and cultural scenarios.

While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overall ageing of the European population and improving survival of patients with coronary heart disease has created a large population of older adults eligible for secondary prevention. Despite the established efficacy of cardiovascular medications, suboptimal adherence reduces their effectiveness and is the primary reason for suboptimal clinical benefit, contributing significantly to worsening of diseases and deaths at the population level. SECURE will be the first trial testing the efficacy of a fixed dose combination (FDC) polypill for secondary cardiovascular prevention in the elderly population (≥ 65 years old). The main objective is to evaluate the potential benefit of the FDC as a component of a cost-effective, globally available and comprehensive treatment strategy for secondary prevention of cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, stroke, and hospitalisation requiring revascularisation) as compared to standard therapy (the three components of the polypill given separately). As part of the secondary endpoints, SECURE will compare the effect of both strategies on adherence and intermediate measures of risk factor control such as lipids and blood pressure. Importantly, it will also measure the pharmacoeconomic impact of the FDC intervention as well as regional differences in all outcomes. The five-year project will thus involve subjects from seven different countries: Spain, Italy, France, Germany, Hungary, Poland and the Czech Republic. The findings and conclusions obtained in SECURE will allow the drafting of clinical guidelines and recommendations that will provide useful guidance and will serve as a reference framework for all stakeholders involved in tackling major challenges related to secondary prevention and treatment of chronic diseases in the elderly population.